VIROMED MEDICAL AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.3 EUR | 0.00% |
|
-7.26% | -42.50% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Capitalization 1 | - | - | - |
| Enterprise Value (EV) 1 | - | - | - |
| P/E ratio | -76.7 x | 10.5 x | 2.95 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Price to Book | 3.24 x | 2.45 x | 1.34 x |
| Nbr of stocks (in thousands) | - | - | - |
| Reference price 2 | 2.300 | 2.300 | 2.300 |
| Announcement Date | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net sales 1 | 16.6 | 46.6 | 79.2 |
| EBITDA 1 | 0.2 | 7.5 | 23 |
| EBIT 1 | - | 7.3 | 22.9 |
| Operating Margin | - | 15.67% | 28.91% |
| Earnings before Tax (EBT) 1 | -0.8 | 6.5 | 22.5 |
| Net income 1 | -0.5 | 4.5 | 15.8 |
| Net margin | -3.01% | 9.66% | 19.95% |
| EPS 2 | -0.0300 | 0.2200 | 0.7800 |
| Free Cash Flow 1 | -7.8 | 2.7 | 15.5 |
| FCF margin | -46.99% | 5.79% | 19.57% |
| FCF Conversion (EBITDA) | - | 36% | 67.39% |
| FCF Conversion (Net income) | - | 60% | 98.1% |
| Dividend per Share | - | - | - |
| Announcement Date | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Debt 1 | 7.6 | 4.8 | - |
| Net Cash position 1 | - | - | 10.6 |
| Leverage (Debt/EBITDA) | 38 x | 0.64 x | - |
| Free Cash Flow 1 | -7.8 | 2.7 | 15.5 |
| ROE (net income / shareholders' equity) | -3.7% | 24% | 45.4% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | 0.7100 | 0.9400 | 1.720 |
| Cash Flow per Share 2 | -0.3800 | 0.1300 | 0.7700 |
| Capex 1 | 0.3 | 0.1 | 0.2 |
| Capex / Sales | 1.81% | 0.21% | 0.25% |
| Announcement Date | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.3
EUR
Average target price
10.4
EUR
Spread / Average Target
+352.17%
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- Q11 Stock
- Financials Viromed Medical AG
